beta-Amyloid (1-42), human, HFIP-treated, a 42-amino acid peptide that has been treated with HFIP from beta-Amyloid (1-42), human (HY-P1363A), is a brain-penetrant amyloid protein fragment, which can be used in research on Alzheimers disease and Downs syndrome. beta-Amyloid (1-42), human, HFIP-treated remaining as a monomer exhibits antioxidant and neuroprotective effects. beta-Amyloid (1-42), human, HFIP-treated, after being dissolved in DMSO to form the stock solution, on the one hand, can form soluble oligomers (AbetaOs) when incubated at 4C, which have synaptic toxicity and neurotoxicity, on the other hand, it can be incubated at 37C to form insoluble fibrils, with lower neurotoxicity, and participating in the oxidative damage process. Abeta42 oligomers bind to various neuronal surface receptors (such as PrPc, mGluR5, NMDA receptors, etc.), triggering oxidative stress, calcium homeostasis imbalance, and synaptic toxicity via activating downstream signaling pathways, leading to neuronal dysfunction and death[1][2][3][4][5][6][7].
Molecular Weight:
4514.04
Purity:
99.89
CAS Number:
[107761-42-2]
Formula:
C203H311N55O60S
Target:
Amyloid-beta
Application Notes:
MCE Product type: Peptides
* VAT and and shipping costs not included. Errors and price changes excepted
